DEVELOPMENT OF A TREATMENT DECISION-MAKING TOOL FOR SICKLE CELL DISEASE MANAGEMENT: THE MANAGE, MONITOR, REALIZE FRAMEWORK
F Bernaudina, AA Zayedb, KA Aniec,d, ME Fieldse, ES Klingsf, C Lobog, O Mbomah, SL Sarafi, F Montealegre-Golcherj, W Smithk
a Centre Hospitalier Intercommunal Créteil, Créteil, France
b Inherited Blood Disorders Center, Qatif Central Hospital, Qatif Health Network, Qatif, Kingdom of Saudi Arabia
c Faculty of Medicine, Imperial College London, London, United Kingdom
d Brent Sickle Cell and Thalassaemia Centre, Department of Haematology, London North West University Healthcare NHS Trust, London, United Kingdom
e Division of Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, United States
f The Pulmonary Center, Boston University Chobanian & Avedisian School of Medicine, Boston, United States
g Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti (Hemorio), Rio de Janeiro, Brazil
h Helios Universitätsklinikum Wuppertal, Wuppertal, Germany
i Comprehensive Sickle Cell Center, Section of Hematology-Oncology, University of Illinois Hospital, Chicago, United States
j Pfizer Inc, New York, United States
k Division of General Internal Medicine, Department of Medicine, Virginia Commonwealth University, Medical College of Virginia Campus, Richmond, United States
Ver másLido
461
Vezesque se leu este artigo
139
Total PDF
322
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 6 | 32 | 17 | 49 |
| 2025 5 | 60 | 14 | 74 |
| 2025 4 | 37 | 8 | 45 |
| 2025 3 | 45 | 9 | 54 |
| 2025 2 | 37 | 18 | 55 |
| 2025 1 | 28 | 10 | 38 |
| 2024 12 | 27 | 15 | 42 |
| 2024 11 | 31 | 28 | 59 |
| 2024 10 | 25 | 20 | 45 |
